TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

10 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Dementia / Alzheimer's

    Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

    Testing a brain stimulation approach to study memory and thinking in people with early

    💵 May compensate

    📍 Massachusetts General Hospital · Charlestown, MA · Get directions →

    The project is a placebo-controlled study that aims to use closed-loop transcranial alternating current stimulation (tACS) to study patients with symptoms of mild cognitive impairment which is likely due to Alzheimer's disease or another form of dementia (AD-MCI). Patients will undergo an EEG and complete some questionnaires and computer tasks during each study visit.

    ✓ Study care freeAges 50–80Learn more →
  • Dementia / Alzheimer's

    Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

    Testing an Alzheimer’s treatment in people with dementia and gum infection

    💵 May compensate

    📍 Banner Alzheimer's Institute · Phoenix, AZ · +38 more US sites · Get directions →

    This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection.

    ✓ Study care freePhase 2Ages 55–80Learn more →
  • Dementia / Alzheimer's

    Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

    Testing a brain scan tracer to measure inflammation in dementia

    💵 May compensate

    📍 Washington University School of Medicine · St Louis, MO · Get directions →

    This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called \[11C\]-CS1P1 to identify inflammation in the brain by testing with healthy older adults and with cognitively impaired older adults.

    ✓ Study care freeAges 50+Learn more →
  • Dementia / Alzheimer's

    Intervention for Communication Quality of Life in Primary Progressive Aphasia

    Testing an online speech and language program to improve communication and quality of life for

    💵 May compensate

    📍 University of Texas · Austin, TX · Get directions →

    The goal of this clinical trial is to learn whether a personalized, multi-component, virtual speech language treatment program can improve communication and quality of life for adults with primary progressive aphasia (PPA) and their primary communication partners. The study will enroll participants who speak English and/or Spanish.

    ✓ Study care freeAges 40+Learn more →
  • Type 2 diabetes

    A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

    Testing whether CX11 tablets are safe and work in people with type 2 diabetes not well controlled on

    💵 May compensate

    📍 Central Research Associates - Flourish - PPDS · Birmingham, AL · +30 more US sites · Get directions →

    This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Type 2 diabetes

    HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

    Testing different doses of a treatment to see safety and effects on blood sugar in people with type

    💵 May compensate

    📍 Alliance Clinical Canoga Park (Hope Clinical Research) · Canoga Park, CA · +24 more US sites · Get directions →

    Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Type 2 diabetes

    Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

    Testing how semaglutide affects blood sugar and weight in people with spinal cord injury and type 2

    💵 May compensate

    📍 University Health - Texas Diabetic Institute · San Antonio, TX · +1 more US site · Get directions →

    It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Type 2 diabetes

    Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers

    Testing software that helps healthcare providers choose diabetes medicines for type 2 diabetes

    💵 May compensate

    📍 University of Virginia Center for Diabetes Technology · Charlottesville, VA · Get directions →

    Decision Support System (Software) for multi antidiabetic drug therapy use in type 2 diabetes (T2D).

    ✓ Study care freeAges 18+Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Low-Dose Pioglitazone in Patients With NASH (AIM 2)

    Testing a low-dose diabetes medicine to see effects on liver changes in NASH

    💵 May compensate

    📍 University of Florida · Gainesville, FL · Get directions →

    To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

    ✓ Study care freePhase 2Ages 21–75Learn more →